Literature DB >> 20566843

Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis.

Yoshiyasu Esaki1, Youxian Li, Daiji Sakata, Chengcan Yao, Eri Segi-Nishida, Toshiyuki Matsuoka, Kazuhiko Fukuda, Shuh Narumiya.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis (MS). Although prostaglandin (PG) concentrations are increased in cerebrospinal fluid of MS patients, the role of PGs in MS is unknown. We examined this issue by subjecting mice deficient in each PG receptor type or subtype to EAE induction and using agonists or antagonists selective for each of the four PGE receptor (EP) subtypes. Among PG receptor-deficient mice, only EP4(-/-) mice manifested significant suppression of EAE, which was mimicked in wild-type mice and to a greater extent, in EP2(-/-) mice by administration of the EP4 antagonist ONO-AE3-208 during the immunization phase. EP4 antagonism during immunization also suppressed the generation of antigen-specific T helper (Th) 1 and Th17 cells in wild-type mice and to a greater extent, in EP2(-/-) mice. ONO-AE3-208 administration at EAE onset had little effect on disease severity, and its administration throughout the experimental period did not cause significant reduction of the peak of disease, suggesting that, in addition to its facilitative action during the immunization phase, EP4 exerts a preventive action in the elicitation phase. Administration of the EP4 agonist ONO-AE1-329 at EAE onset delayed and suppressed disease progression as well as inhibited the associated increase in permeability of the blood-brain barrier. Thus, PGE(2) exerts dual functions in EAE, facilitating Th1 and Th17 cell generation redundantly through EP4 and EP2 during immunization and attenuating invasion of these cells into the brain by protecting the blood-brain barrier through EP4.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20566843      PMCID: PMC2901475          DOI: 10.1073/pnas.0915112107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway.

Authors:  Katsuichi Miyamoto; Sachiko Miyake; Miho Mizuno; Nobuyuki Oka; Susumu Kusunoki; Takashi Yamamura
Journal:  Brain       Date:  2006-07-10       Impact factor: 13.501

2.  Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation.

Authors:  Hania Kebir; Katharina Kreymborg; Igal Ifergan; Aurore Dodelet-Devillers; Romain Cayrol; Monique Bernard; Fabrizio Giuliani; Nathalie Arbour; Burkhard Becher; Alexandre Prat
Journal:  Nat Med       Date:  2007-09-09       Impact factor: 53.440

3.  Experimental allergic encephalomyelitis-prophylactic and therapeutic treatment with the cyclooxygenase inhibitor piroxicam (Feldene).

Authors:  F Weber; R Meyermann; K Hempel
Journal:  Int Arch Allergy Appl Immunol       Date:  1991

4.  Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion.

Authors:  Carlo Chizzolini; Rachel Chicheportiche; Montserrat Alvarez; Casimir de Rham; Pascale Roux-Lombard; Sylvie Ferrari-Lacraz; Jean-Michel Dayer
Journal:  Blood       Date:  2008-08-12       Impact factor: 22.113

5.  Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease.

Authors:  Athena Kalyvas; Samuel David
Journal:  Neuron       Date:  2004-02-05       Impact factor: 17.173

6.  COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression.

Authors:  Jia Ni; Ying-Yi Shu; Yi-Na Zhu; Yun-Feng Fu; Wei Tang; Xiang-Gen Zhong; Hui Wang; Yi-Fu Yang; Jin Ren; Ming-Wei Wang; Jian-Ping Zuo
Journal:  J Neuroimmunol       Date:  2007-04-17       Impact factor: 3.478

Review 7.  The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?

Authors:  Howard L Weiner
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422

8.  Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis.

Authors:  Suzana Marusic; Michael W Leach; Jeffrey W Pelker; Mihai L Azoitei; Naonori Uozumi; Junqing Cui; Marina W H Shen; Charlene M DeClercq; Joy S Miyashiro; Brenda A Carito; Paresh Thakker; David L Simmons; John P Leonard; Takao Shimizu; James D Clark
Journal:  J Exp Med       Date:  2005-09-19       Impact factor: 14.307

9.  Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling.

Authors:  Katia Boniface; Kristian S Bak-Jensen; Ying Li; Wendy M Blumenschein; Mandy J McGeachy; Terrill K McClanahan; Brent S McKenzie; Robert A Kastelein; Daniel J Cua; René de Waal Malefyt
Journal:  J Exp Med       Date:  2009-03-09       Impact factor: 14.307

Review 10.  Physiology and pathophysiology of prostanoid receptors.

Authors:  Shuh Narumiya
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2007-12       Impact factor: 3.493

View more
  49 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

Review 2.  Regulation of TH17 cell differentiation by innate immune signals.

Authors:  Gonghua Huang; Yanyan Wang; Hongbo Chi
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

3.  Modulation of dendritic cell function by PGE2 and DHA: a framework for understanding the role of dendritic cells in neuroinflammation.

Authors:  Doina Ganea; Virginia Kocieda; Weimin Kong; Jui-Hung Yen
Journal:  Clin Lipidol       Date:  2011-06

Review 4.  Eicosanoids in metabolic syndrome.

Authors:  James P Hardwick; Katie Eckman; Yoon Kwang Lee; Mohamed A Abdelmegeed; Andrew Esterle; William M Chilian; John Y Chiang; Byoung-Joon Song
Journal:  Adv Pharmacol       Date:  2013

5.  Prostaglandin E2 Inhibition of IL-27 Production in Murine Dendritic Cells: A Novel Mechanism That Involves IRF1.

Authors:  Kirsten M Hooper; Jui-Hung Yen; Weimin Kong; Kate M Rahbari; Ping-Chang Kuo; Ana M Gamero; Doina Ganea
Journal:  J Immunol       Date:  2017-01-06       Impact factor: 5.422

6.  Lipoic Acid Stimulates cAMP Production in Healthy Control and Secondary Progressive MS Subjects.

Authors:  Sarah E Fiedler; Vijayshree Yadav; Amelia R Kerns; Catherine Tsang; Sheila Markwardt; Edward Kim; Rebecca Spain; Dennis Bourdette; Sonemany Salinthone
Journal:  Mol Neurobiol       Date:  2017-11-15       Impact factor: 5.590

Review 7.  Regulation of immune responses by prostaglandin E2.

Authors:  Pawel Kalinski
Journal:  J Immunol       Date:  2012-01-01       Impact factor: 5.422

8.  mPGES1-Dependent Prostaglandin E2 (PGE2) Controls Antigen-Specific Th17 and Th1 Responses by Regulating T Autocrine and Paracrine PGE2 Production.

Authors:  Damian Maseda; Elizabeth M Johnson; Lindsay E Nyhoff; Bridgette Baron; Fumiaki Kojima; Ashley J Wilhelm; Martin R Ward; Jerold G Woodward; David D Brand; Leslie J Crofford
Journal:  J Immunol       Date:  2017-12-13       Impact factor: 5.422

Review 9.  Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).

Authors:  Cris S Constantinescu; Nasr Farooqi; Kate O'Brien; Bruno Gran
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

10.  Decreased RORC-dependent silencing of prostaglandin receptor EP2 induces autoimmune Th17 cells.

Authors:  David M Kofler; Alexander Marson; Margarita Dominguez-Villar; Sheng Xiao; Vijay K Kuchroo; David A Hafler
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.